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Disease mutations reveal residues 
critical to the interaction of P4-
ATPases with lipid substrates
Rasmus H. Gantzel1, Louise S. Mogensen1, Stine A. Mikkelsen1, Bente Vilsen1, Robert S. 
Molday2,3, Anna L. Vestergaard  1,4 & Jens P. Andersen  1
Phospholipid flippases (P4-ATPases) translocate specific phospholipids from the exoplasmic to the 
cytoplasmic leaflet of membranes. While there is good evidence that the overall molecular structure 
of flippases is similar to that of P-type ATPase ion-pumps, the transport pathway for the “giant” lipid 
substrate has not been determined. ATP8A2 is a flippase with selectivity toward phosphatidylserine 
(PS), possessing a net negatively charged head group, whereas ATP8B1 exhibits selectivity toward the 
electrically neutral phosphatidylcholine (PC). Setting out to elucidate the functional consequences of 
flippase disease mutations, we have identified residues of ATP8A2 that are critical to the interaction 
with the lipid substrate during the translocation process. Among the residues pinpointed are I91 and 
L308, which are positioned near proposed translocation routes through the protein. In addition we 
pinpoint two juxtaposed oppositely charged residues, E897 and R898, in the exoplasmic loop between 
transmembrane helices 5 and 6. The glutamate is conserved between PS and PC flippases, whereas the 
arginine is replaced by a negatively charged aspartate in ATP8B1. Our mutational analysis suggests 
that the glutamate repels the PS head group, whereas the arginine minimizes this repulsion in ATP8A2, 
thereby contributing to control the entry of the phospholipid substrate into the translocation pathway.
P4-ATPases, known as flippases, are lipid pumps that contribute to the phospholipid asymmetry of cellular mem-
branes, thereby being crucial to a number of physiologically important functions. Fueled by ATP, the flippases 
translocate specific phospholipids such as phosphatidylserine (PS), phosphatidylethanolamine (PE), or phos-
phatidylcholine (PC) from the exoplasmic to the cytoplasmic membrane leaflet1–9. Flippases constitute the largest 
subfamily of the P-type ATPases, with 14 different human genes of 36 human P-type ATPase genes in total. The 
phospholipid specificity seems to differ among the human flippases, but is well characterized only for some of 
the family members, such as the PS flippases ATP8A1 (PS > PE, no PC), ATP8A2 (PS > PE, no PC), ATP11A 
(PS > PE, no PC), and ATP11C (PS > PE, no PC), while being somewhat controversial for ATP8B1 (PC, PS?) and 
unknown for several others1–8. ATP8B1 was originally considered a PS flippase1, but recent studies in HeLa and 
CHO-K1 cells indicate that ATP8B1 (as well as ATP8B2 and ATP10A) selectively translocate phosphatidylcholine 
(PC)8, 9. The difference in charge of the head group (PS negatively charged, PE and PC neutral), but probably also 
its size and other chemical characteristics, may form the basis for the selectivity.
P4-ATPase gene mutations result in a broad variety of pathophysiological conditions. Severe neurological 
manifestations have been reported for mutations of the neuronal flippase ATP8A210, 11. The largest group of 
patients with flippase defects suffer from the intrahepatic cholestasis diseases PFIC1 (progressive familial intra-
hepatic cholestasis type 1) and BRIC1 (benign recurrent intrahepatic cholestasis type 1) caused by mutation of 
the liver-expressed ATP8B11, 12, 13. BRIC1 is the mildest variant, with an onset in childhood of recurring epi-
sodes of cholestasis, but without detectable liver damage under remission. The more debilitating PFIC1 usually 
debuts within the first year of life and progresses to end-stage liver disease during the adolescence. The underlying 
molecular pathophysiology of these disorders is not clear, but the accumulation of PC or PS (depending on what 
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the lipid substrate of ATP8B1 actually is) in the outer leaflet caused by reduced ATP8B1 activity might lead to 
shedding of membrane protrusions into the bile and inactivation of the bile transporter ABCB111, 8.
Amino acid sequence comparison suggests an overall molecular structure of flippases similar to that known 
from X-ray crystallography of the ion-pumping prototypical P-type ATPases Ca2+-ATPase (SERCA) and 
Na+,K+-ATPase, with cytoplasmic so-called phosphorylation (P), nucleotide-binding (N) and actuator (A) 
domains that mediate ATP hydrolysis by catalysing formation and decomposition of a phosphorylated inter-
mediate (Fig. 1a), and a transmembrane domain consisting of 10 helices (M1–M10), which likely mediate the 
transport of the specific lipid substrate2, 14–17. A structural model of bovine ATP8A2 (in the following abbreviated 
bATP8A2) was built based on the high-resolution crystal structures of SERCA in E2 and E2P states and refined 
by molecular dynamics simulation (Fig. 2)14. However, the flipping mechanism and the transport pathway for 
the lipid substrate, which is about 10-fold larger than the inorganic ions transported by the ion pumps, pose an 
enigma referred to as the giant substrate problem14, 16, 17. One proposed solution based on the structural model-
ling in combination with mutagenesis is that lipid flipping occurs by movement of the polar lipid head group in 
a groove on the surface of the protein, being propelled by a cluster of hydrophobic residues undergoing confor-
mational changes, and with the lipid hydrocarbon chains following passively, still in the membrane lipid phase 
(“hydrophobic gate pathway”)14. Information on the translocation pathway has also emerged from experiments 
swapping PC and PS selectivity between the yeast flippases Dnf1 and Drs218. However, most of the residues pin-
pointed in this way as determinants of the head-group selectivity and, thus, as putative interaction sites for the 
head group during the translocation are located closer to the cytoplasmic surface than to the exoplasmic surface 
at the so-called “exit gate”, which is puzzling, because the lipid is translocated from the exoplasmic leaflet toward 
the cytoplasmic leaflet, thus expectedly requiring a means of discriminating between different phospholipid head 
groups near the exoplasmic surface.
It was previously shown that bATP8A2 can be expressed in HEK293T cells and purified by immunoaffinity 
chromatography in sufficient amounts for detailed studies of its reaction cycle, which is activated specifically 
by PS and PE, but not by PC6, 15. With this methodology, we set out to study the functional consequences of 
Figure 1. Flippase reaction cycle. (a) The scheme is based on functional similarities to the ion transporting 
P-type ATPases15. E1, E1P, E2P, and E2 are the major enzyme conformational states, the “P” indicating covalently 
bound phosphate. Reactions are numbered 1–6. The phospholipid substrate, PL, enters the cycle from the 
exoplasmic leaflet of the lipid bilayer by binding to the E2P phosphoenzyme (Reaction 1), thereby stimulating 
the dephosphorylation (Reaction 2) and release of the lipid toward the cytoplasmic leaflet (Reaction 4) as 
a consequence of the E2 to E1 transition (Reaction 3). The transition to E1 allows the enzyme to become 
rephosphorylated (Reaction 5). The stimulation of dephosphorylation by the lipid substrate is analogous to 
the activation of Na+,K+-ATPase dephosphorylation by K+ binding to E2P from the extracellular side of the 
membrane2. In further analogy with the modes of binding and transport of K+ by the Na+,K+-ATPase, the 
parentheses in E2(PL) indicate that the PL is bound to the protein in an occluded state, where the protein 
conformational change to E1 is required before the PL can be released toward the cytoplasmic side. In E2P·PL 
and E1·PL the · indicates that PL in these complexes is able to dissociate (to the exoplasmic leaflet and the 
cytoplasmic leaflet, respectively). (b) Rate constants relating to the rate-limiting dephosphorylation reaction and 
subsequent conformational change. Under the experimental conditions applied here, the dephosphorylation is 
essentially irreversible, because the concentration of inorganic phosphate in the medium is low.
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ATP8B1 liver disease mutations by introducing them in bATP8A2. We report here results pinpointing residues 
of bATP8A2 that seem to interact closely with the lipid head group during the translocation process. The two 
juxtaposed residues E897 and R898 may be part of an exoplasmic facing “entry gate” of the translocation pathway.
Results
Mutants and expression. ATP8B1 mutations L127P and E981K have been reported for patients with 
PFIC1, whereas ATP8B1 I344F is a BRIC1 mutation13, 19. The equivalent mutations of bATP8A2 are I91P, E897K, 
and L308F. Table 1 lists these and other mutations studied in the present work. The locations in the modelled 
bATP8A2 E2P structure of the most important of the residues studied here are indicated in Fig. 2, which also 
indicates the position of I364, previously shown to be a critical element in the transport mechanism of human 
as well as bovine ATP8A2 (“hydrophobic gate residue”)14. All the mutant bATP8A2 proteins could be expressed 
together with the accessory CDC50A subunit in HEK293T cells and purified in amounts sufficient for detailed 
functional studies (Table 1). The lowest expression level (12% of wild type) was seen for the I91P mutant. A mark-
edly reduced expression level relative to the wild type was seen for the mutants I91A, E897K, and E897R, as well 
(~30%, Table 1), whereas expression levels were higher for the other mutants including L308F, which showed wild 
type-like expression.
Figure 2. Structural model of transmembrane domains M1-M10 of bATP8A2. The M1-M2 hairpin is coloured 
purple, M3-M4 green, M5-M6 ochre, and M7-M10 grey. The model was previously published for both E2 and 
E2P states14 and is here shown for E2P in front (a) and back (b) views, respectively, along the membrane plane, 
with the side chains of the most important residues mentioned in the text indicated by stick representation 
(carbon atoms yellow, oxygen red, and nitrogen blue). The exoplasmic side is down and the cytoplasmic side up. 
Hence, the phospholipid is transported upwards.
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Maximal ATPase activity and apparent PS and PE lipid affinities. The expressed bATP8A2/
CDC50A protein complexes were purified by detergent solubilization and immunoaffinity chromatography and 
reconstituted in vesicular form with PC as the only lipid present by detergent removal by dialysis. For assay of 
ATPase activity, the reconstituted proteoliposomes were solubilized with CHAPS detergent, and various con-
centrations of PS or PE (together with PC, keeping the total lipid concentration constant) were added, as well 
as ATP. This procedure allowed determination of the maximal rate of ATP hydrolysis per mg of pure bATP8A2 
protein (Vmax) and the apparent affinities for PS and PE (as measured by the K0.5 values for stimulation of the 
ATP hydrolysis by the lipid, Figs 3 and 4, Table 1). Under optimal conditions at saturating PS concentration and 
37 °C the Vmax of the wild type bATP8A2 was 97 μmol/min/mg bATP8A2 protein (average of measurements on 
14 preparations over more than a year), corresponding to a turnover rate (kcat) of 209 s–1. This value is of the same 
order of magnitude as the maximal turnover rates determined for the ion-pumping P-type ATPases Ca2+-ATPase 
(SERCA) and Na+,K+-ATPase, but is 1–2 orders of magnitude higher than the turnover rates that have been 
measured for the yeast homolog Drs2, which seems, at least in part, due to the longer, auto-inhibitory C-terminus 
of Drs22, 20. Like the wild type bATP8A2 protein, all the mutants required the presence of PS or PE for activation, 
PS being the preferred substrate with higher affinity and giving higher Vmax than PE. Only diminutive ATPase 
activity was seen with PC alone (at approx. 3000 μM PC the activity of WT and all mutants was less than 6% of the 
maximal PS-stimulated activity, data points at 0 μM PS in Figs 3 and 4).
The I91P mutation led to a dramatic reduction of the activity, the Vmax being ~5-fold reduced with PS as the 
activating lipid and ~17-fold with PE, relative to the wild type, whereas the Vmax was wild type-like for I91A with 
Mutanta
Expressionb ATPase activity stimulated by PSc ATPase activity stimulated by PEc
% of WT n
Vmax with PS, 
µmol/min/mg n K0.5 for PS, µM n
Vmax with PE, 
µmol/min/mg n K0.5 for PE, µM n
WT 100 ± 12 14 97 ± 4 31 34 ± 1 342 50 ± 3 26 386 ± 16 264
I91P (L127P) 12 ± 2*** 4 18 ± 2 (5.4x↓)*** 6
96 ± 6 
(2.8x↑)*** 60
3 ± 0.4 
(17x↓)*** 2
1245 ± 522 
(3.2x↑)*** 20
I91A 29 ± 3** 3 88 ± 15 (1.1x↓) 7 65 ± 4 (1.9x↑)*** 70 46 ± 9 (1.1x↓) 4
516 ± 48 
(1.3x↑) 40
L308F (I344F) 104 ± 34 2 85 ± 1 (1.1x↓) 4 151 ± 10 (4.4x↑)*** 40 28 ± 2 (1.8x↓)** 4
923 ± 65 
(2.4x↑)*** 40
L308A 88 ± 18 2 96 ± 5 (1.0x) 5 38 ± 2 (1.1x↑) 50 35 ± 4 (1.4x↓) 4 430 ± 18 (1.1x↑) 39
E897K (E981K) 29 ± 7* 2 19 ± 4 (5.1x↓)*** 8
11 ± 1 
(3.1x↓)*** 78 9 ± 3 (5.6x↓)*** 5
422 ± 48 
(1.1x↑) 50
E897A 54 ± 18 3 41 ± 8 (2.4x↓)*** 8
17 ± 1 
(2.0x↓)*** 79 33 ± 8 (1.5x↓)** 10
349 ± 30 
(1.1x↓) 104
E897D 98 ± 5 2 92 ± 3 (1.1x↓) 4 43 ± 3 (1.3x↑) 40 50 ± 7 (1.0x) 4 495 ± 31 (1.3x↑) 39
E897Q 78 ± 10 3 60 ± 3 (1.6x↓)* 5 17 ± 1 (2.0x↓)*** 50 38 ± 13 (1.3x↓) 5
255 ± 15 
(1.5x↓) 50
E897F 45 ± 7 2 31 ± 4 (3.1x↓)*** 4
7 ± 1 
(4.9x↓)*** 39 71 ± 12 (1.4x↑)* 4
476 ± 28 
(1.2x↑) 39
E897R 29 ± 1* 2 10 ± 1 (9.7x↓)*** 4
13 ± 1 
(2.6x↓)*** 40
3 ± 0.1 
(17x↓)*** 5
1205 ± 59 
(3.1x↑)*** 50
R898A 66 ± 8 5 76 ± 12 (1.3x↓) 8 53 ± 3 (1.6x↑)*** 80
27 ± 3 
(1.9x↓)*** 9
353 ± 30 
(1.1x↓) 90
R898D 89 ± 12 3 83 ± 11 (1.2x↓) 5 126 ± 4 (3.7x↑)*** 60
9 ± 0.3 
(5.6x↓)*** 4
1069 ± 140 
(2.8x↑)*** 39
R898E 82 ± 13 2 59 ± 13 (1.6x↓)** 6
97 ± 5 
(2.9x↑)*** 70
12 ± 4 
(4.2x↓)*** 5
719 ± 93 
(1.9x↑)*** 50
R898K 79 ± 5 2 105 ± 22 (1.1x↑) 4 30 ± 1 (1.1x↓) 50 43 ± 7 (1.2x↓) 4 591 ± 49 (1.5x↑) 50
E897R_R898E 56 ± 1 2 35 ± 2 (2.8x↓)*** 4
52 ± 3 
(1.5x↑)*** 40
11 ± 5 
(4.5x↓)*** 4
888 ± 37 
(2.3x↑)*** 40
D99A 85 ± 2 2 85 ± 14 (1.1x↓) 6 40 ± 1 (1.2x↑) 40 17 ± 4 (2.9x↓)*** 4
541 ± 29 
(1.4x↑) 40
R105A 62 ± 9 2 48 ± 6 (2.0x↓)** 4 45 ± 3 (1.3x↑)** 79 25 ± 2 (2.0x↓)* 3
487 ± 47 
(1.3x↑) 27
Table 1. Analysis of expression and ATPase activity with PS and PE. Data deviating significantly from 
WT according to the one-way ANOVA test (see further in Methods) are marked with *(0.05 > P > 0.01), 
**(0.001 < P < 0.01), and ***(P < 0.001). aWild type (WT) and mutant bATP8A2 proteins. Homologous disease 
mutations in human ATP8B1 are indicated in parentheses. bAverage of expression levels calculated relative to 
the wild type of the same transfection experiment, n indicating the number of transfection experiments. cVmax 
refers to the ATPase activity at the highest lipid concentration examined (1000 µM PS or 2000 µM PE), K0.5 
(substrate concentration giving half maximum activation) was obtained by nonlinear regression curve fitting 
(see Figs 3 and 4), n indicating the number of data points in the regression. In parentheses is shown fold change 
relative to wild type (arrow pointing upward/downward for increase/decrease).
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either lipid. The apparent affinity of I91P was ~3-fold reduced (3-fold increased K0.5) for both PS and PE, whereas 
the reduction of the apparent affinity was less pronounced for I91A (Fig. 3a,c and Table 1).
Replacement of L308 with the even larger hydrophobic phenylalanine side chain led to a wild type-like Vmax 
with PS as the activating lipid, but the apparent affinity was notably reduced for both lipid substrates, ~4-fold 
for PS and ~2-fold for PE, as was the maximal rate with PE (~2-fold, Fig. 3a,c and Table 1). The L308A mutant 
showed more wild type-like functional properties compared with L308F (Table 1).
The E897K mutation resulted in marked ~5- and ~6-fold reductions of Vmax with PS and PE as activating sub-
strates, respectively. Moreover, mutation E897K caused a ~3-fold increase of the apparent affinity for PS relative to 
wild type (3-fold reduced K0.5), but without significant effect on the apparent affinity for PE (Fig. 3a,c and Table 1). 
For further elucidation of the functional role of the negatively charged E897 side chain, additional mutations to 
E897 were introduced: E897A, E897D, E897Q, E897F, and E897R. The latter mutation resulted in dramatic 10- 
and 17-fold reductions of Vmax with PS and PE as activating substrates, respectively, whereas the effects on Vmax 
were much less pronounced for the other E897 mutants. The E897D mutant, retaining a carboxylate group in the 
side chain, was rather wild type-like for all the parameters determined. As with E897K, significant increases of 
the apparent affinity for PS (reduced K0.5), relative to wild type, were observed for the mutants E897A (~2-fold), 
E897Q (~2-fold), E897F (~5-fold), and E897R (~3-fold), whereas the apparent PE affinity was wild type-like or 
less affected than the apparent PS affinity, or even reduced (E897R), see Fig. 3b,d and Table 1.
Mutants with alterations to the neighbouring arginine, R898, were also analysed (Fig. 4 and Table 1), showing 
insignificant or rather moderate (R898E) reductions of Vmax with PS as the activating lipid and larger reductions 
of Vmax with PE, particularly the R898D and R898E mutants where the positively charged arginine side chain is 
replaced by a negatively charged carboxylate side chain. These mutations also markedly reduced the apparent 
affinity for both lipid substrates (K0.5 increased 3- to 4-fold for PS and 2- to 3-fold for PE). The alanine substitution 
reduced the apparent affinity only for PS (~2-fold).
A swap mutant, E897R_R898E, was constructed to examine the possibility that E897 and R898 interact 
through a salt bridge (see Fig. 5). An essential finding with this double mutant was that the R898E mutation 
compensates the drastic 10- and 17-fold reductions of Vmax with PS and PE, respectively, observed for the single 
mutation E897R, thus resulting in only ~3- and ~5-fold reductions of Vmax, respectively, in the swap mutant, even 
though the point mutation R898E by itself reduces Vmax. Furthermore, the apparent PS affinity of the E897R_
R898E mutant deviated less (1.5-fold reduction) from that of the wild type than the PS affinities of the singly sub-
stituted mutants E897R (2.6-fold increase) and R898E (2.9-fold reduction). The apparent PE affinity of the swap 
Figure 3. Lipid substrate dependence of ATPase activity of disease mutants and additional E897 mutants. The 
ATPase activity of the wild type bATP8A2 (WT) and the indicated mutants was determined at the indicated 
concentrations of PS (a, b) or PE (c, d). The total lipid concentration was fixed at 2.5 mg/mL (the remainder 
constituted by PC). The activity is shown as % of Vmax (the absolute value of Vmax is given in Table 1). The lines 
represent best fits of the Hill equation V/Vmax = [L]H/(K0.5H + [L]H), where the ligand L is either PS or PE. The 
Hill coefficient H resulting from the regression was ∼1 in all cases. The extracted K0.5 values and statistics are 
shown in Table 1.
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mutant was 2.3-fold reduced, again being intermediate between E897R and R898E (3.1- and 1.9-fold reduced, 
respectively, Table 1).
The mutations D99A and R105A were also introduced in bATP8A2 and studied, because the structural model 
suggests potentially important interactions of D99 and R105 with R898 (see Discussion and Fig. 5a). For the 
D99A mutant, the Vmax with PS as activating lipid and the apparent PS and PE affinities were wild type-like, 
whereas Vmax with PE was ~3-fold reduced, relative to the wild type. For the R105A mutant, the Vmax was reduced 
~2-fold, both with PS and with PE as activating lipid. The effects of mutation R105A on the apparent lipid affini-
ties were slight, 1.3-fold reduction for PS, and for PE the same was seen, although in the latter case the difference 
from wild type was not statistically significant (Table 1).
Discussion
Of the three studied bATP8A2 mutations equivalent to ATP8B1 disease mutations, I91P and E897K most strongly 
affected the expression level and the Vmax, whereas the L308F mutation reduced the apparent affinities for the PS 
and PE lipid substrates markedly, but did not reduce the expression, and exerted no (for PS) or less (for PE) effect 
on the Vmax than I91P and E897K. Because a selective reduction of affinity may allow partial retention of the lipid 
flipping activity under physiological conditions, the observed differences between the mutants seem consistent 
with the clinical courses of the liver disease in the patients harbouring the ATP8B1 mutations: ATP8B1 L127P 
and E981K, equivalent to bATP8A2 I91P and E897K, give rise to PFIC1, which has a very severe clinical course, 
and ATP8B1 I344F, equivalent to bATP8A2 L308F, causes BRIC1, which has a milder clinical course.
Just like wild type bATP8A2, the bATP8A2 mutants studied required PS or PE to activate ATP hydrolysis, and 
no appreciable activation occurred with PC alone up to approx. 3000 μM, i.e. higher than the concentrations of PS 
and PE required for maximal activity. Hence, there is no indication that the mutations converted bATP8A2 to a 
PC flippase. Nevertheless, some of the observed mutational effects on the PS and PE stimulated ATPase activity of 
bATP8A2 are largely similar to the previously described effects of the equivalent mutations in ATP8B1 and yeast 
Dnf2 on their PC flippase activity measured as uptake of fluorescent NBD-labelled PC in whole cells8, 21 (Table 2). 
Hence, the previous study demonstrating uptake of NBD-PC in HeLa cells expressing wild-type ATP8B1 also 
showed that either of the ATP8B1 mutations L127P and I344F abolishes NBD-PC uptake, although no distinction 
between the effects on Vmax and apparent affinity was possible in this study, because only one probe concentration 
was tested8. In the study of NBD-PC uptake by yeast Dnf2 mutants21, the apparent lipid affinity was determined 
and was found reduced in the N601F mutant (equivalent to bATP8A2 L308F and ATP8B1 I344F) and enhanced 
in E1261K (equivalent to bATP8A2 E897K and ATP8B1 E981K), the latter mutant also showing reduced Vmax. 
These similarities between the effects of equivalent mutations are remarkable, considering that different flippase 
proteins, lipid substrates, and expression systems were studied. However, a wild type-like expression and function 
Figure 4. Lipid substrate dependence of ATPase activity of R898 mutants. The ATPase activity of the wild type 
bATP8A2 (WT) and the indicated mutants was determined at the indicated concentrations of PS (a, b) or PE (c, 
d). The data for R898E and E897R are repeated in (b and d) for direct comparison with E897R_R898E. Further 
information as in the legend to Fig. 3.
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was reported for yeast Dnf2 L264P21, which differs from the robust effects of the corresponding bATP8A2 I91P 
and ATP8B1 L127P mutations (Table 2).
The observed dependence of the ATPase activity of bATP8A2 on the specific lipid substrates PS and PE 
reflects the activation of the rate-limiting dephosphorylation step (E2P to E2) by the binding of these lipids to E2P 
(see reaction cycle in Fig. 1a)15. To appreciate the meaning of the apparent affinities (K0.5 values) extracted from 
the data in Figs 3 and 4, it is helpful to realize that the K0.5 essentially is the Michaelis constant Km of the reaction 
shown in Fig. 1b, hence
–= = +.K K (k k )/k (1)0 5 m cat 1 1
Figure 5. Close up view of the E897-R898 region with alternative R898 side chain rotamers. Side chains of E897 
and R898, as well as the additional residues examined in this study, D99 and R105 (only shown in a), are indicated 
by stick representation. Dotted lines indicate distances shorter than 3.6 Å, i.e. compatible with a salt bridge. The 
shortest distance between R105 guanidine-N and E897 side chain-O is 5.0 Å. (a) Originally modelled rotamer of 
R898 side chain (same as in Fig. 2). (b) Alternative R898 rotamer, where no salt bridge is formed with D99. The 
overall structural model and colour codes for membrane helices and side chains are the same as in Fig. 2.
Present study (bATP8A2, PS)a Ref. 8 (ATP8B1, PC)b Ref. 21 (Dnf2, PC)c
Mutant I91P L308F E897K L127P I344F E981K L264P N601F E1261K
Expression ↓ WT ↓ ↓ WT
n.d.
WT WT WT
Vmax ↓ WT ↓ Lipid uptake ↓ Lipid uptake ↓
WT WT ↓
Apparent affinity for lipid ↓ ↓ ↑ WT ↓ ↑
Table 2. Summary of present results on disease mutants and comparison with previous studies. The mutational 
effects indicated refer to measurements of ATPase activity stimulated by PSa or uptake of fluorescently labelled 
PC (substrate of ATP8B1 and Dnf2) in mammalianb or yeastc cells. A ≥1.5-fold change is considered different 
from wild type and is indicated by arrow pointing upward/downward for increase/decrease (WT = wild type-
like). L127P, I344F, and E981K are disease mutations in ATP8B1 identified in patients. The equivalent mutations 
in the bATP8A2 studied here are I91P, L308F, and E897K, and in yeast Dnf2 L264P, N601F, and E1261K, 
respectively. Only a single PC concentration was tested with ATP8B1, thus precluding distinction between 
effects on Vmax and K0.5b, and E981K was not studied (n.d., not determined)8. In the latter study, the lipid uptake 
was corrected for variation of ATP8B1 protein expression at the surface of the cells, thus being comparable to 
the Vmax value of the present study, which is the rate of ATP hydrolysis per mg of bATP8A2 protein.
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Because the dephosphorylation is rate limiting for the overall ATPase reaction, the kcat corresponds to the 
maximal turnover rate (rate of ATP hydrolysis per enzyme molecule) and is directly proportional to the Vmax 
(here denoting the rate of ATP hydrolysis per mg of enzyme). Hence the Vmax is a co-determinant of the observed 
K0.5 for the phospholipid together with the dissociation constant, k–1/k1, characterizing the “true” or intrinsic 
affinity of E2P for the phospholipid. Based on equation (1) it can be concluded that in those mutants where the 
Vmax (i.e. kcat) is normal or reduced and the K0.5 for the lipid substrate increased (i.e. corresponding to reduced 
apparent affinity), relative to wild type, the mutation must have increased k–1 and/or reduced k1, thus reducing 
the intrinsic affinity for the phospholipid. Such is the case for L308F, both with PS and PE as activating lipid, and 
it is therefore likely that this mutation disturbs a binding site used by either lipid during the translocation. In 
our bATP8A2 structural model (Fig. 2) the L308 side chain projects into the interface between the M3 and M5 
helices close to the region proposed as “exit gate”18, 22, and the bulky phenylalanine substituent may therefore have 
interfered directly with the binding of the lipid substrate here. In the hydrophobic gate pathway hypothesis14 the 
disturbance would be more indirect, perhaps being caused by perturbation of the interaction between M3 and M5 
or the interaction with the accessory subunit known to play a role in the binding of the lipid substrate21, 23. In the 
study of the equivalent yeast Dnf2 mutant N601F a weakened interaction with the accessory subunit was in fact 
inferred by using a mating-based split ubiquitin assay21.
Following the same analysis as outlined above, the reduced apparent affinity of the I91P mutant for PS and 
PE in conjunction with its reduced Vmax values, relative to wild type, suggests that the intrinsic affinity for either 
phospholipid substrate is reduced in I91P. Interestingly, the side chain of I91 is within 3 Å of I364 of M4 in the E2P 
model (Fig. 2). I364 is the central residue in the proposed hydrophobic gate pathway for lipid translocation, the 
position of I364 in the amino acid sequence being equivalent to that of the M4 glutamate that binds and translo-
cates the cations in Ca2+- and Na+,K+-ATPases14. I91 is conserved as isoleucine or leucine in the majority of the 
P4-ATPases (see Fig. 6) and might well participate in hydrophobic interaction in the hydrophobic gate, which 
would be disturbed by the I91P mutation, thus explaining the effect on affinity as well as Vmax.
The glutamate E897 is located in the exoplasmic loop between M5 and M6 at the border of M6 (Figs 2 and 5). 
The E897K mutation reduced both the Vmax and the K0.5 for PS, raising the possibility that the reduced K0.5 is a 
consequence of the reduced kcat rather than of an increase of the intrinsic affinity for PS. However, the relative 
change of Vmax imposed by this mutation is very similar for PS and PE (5- to 6-fold), and yet the K0.5 for PE was 
essentially unchanged (Table 1), which leads us to speculate that most likely the E897K mutation selectively 
increased the “true” affinity for PS relative to PE. A similar explanation seems to hold for the other E897 mutants 
except E897D, which was wild type-like, suggesting that the negatively charged carboxylate group is more impor-
tant than the length of the side chain. The difference between PS and PE is particularly obvious for the E897R 
mutant, which showed reduced K0.5 with PS as activating lipid and increased K0.5 with PE, despite a large reduc-
tion of Vmax in both cases. Taken together, the data support the hypothesis that the lipid substrate passes relatively 
close to the E897 side chain during the transport process in the wild type bATP8A2, such that the net negatively 
charged PS head group senses the negative charge of E897 (or aspartate as substituent), thus being repelled in 
contrast to the neutral PE head group. Mutations to E897 that remove the negative charge or introduce a positive 
charge interacting favorably with the negatively charged PS head group will therefore lead to increased affinity. 
The reduced apparent affinity for PE seen for the E897R substitution could possibly arise from partial steric hin-
drance by the bulky arginine side chain of the access of the lipid head group to a binding site/exoplasmic entry 
of the transport pathway. In the case of the PS head group, such steric hindrance might be compensated by the 
electrostatic attraction to the positively charged arginine side chain.
It is of note that the K0.5 for PS is reduced more in the E897F mutant (∼5-fold) than in any of the other E897 
mutants, still with no reduction of the K0.5 for PE. Hence, the insertion of an aromatic side chain at this position 
not only prevents electrostatic repulsion of PS by E897, but also in some way increases the likelihood that PS will 
bind.
Further, according to the considerations above (i.e. equation (1)), the reduced apparent affinity for PS and PE 
combined with wild type-like or reduced Vmax seen upon replacement of R898 with aspartate or glutamate indi-
cates that these charge-reversing substitutions reduce the intrinsic affinity for either lipid. However, the effect was 
strongest for PS, and the mere removal of the positive charge by the R898A mutation reduced only the PS affinity. 
In addition, little effect was seen for the R898K mutation that retains the positive charge of the side chain. Hence, 
the most reasonable interpretation is that in the wild type the positive charge of the arginine side chain interacts 
favourably with the negatively charged head group of PS during the transport process, and that a negatively 
charged side chain at this position repels not only PS, but also to some extent PE, probably due to closeness to its 
local negative charge at the phosphate group.
Because interaction of R898 with E897 through a salt bridge would be feasible according to the molecular 
modelling (Fig. 5a,b), we examined the swap mutant E897R_R898E. Separately, both of the mutations E897R 
and R898E reduced Vmax with either PS or PE as activating lipid, thus it might have been expected that the double 
mutant would be further inhibited. However, the maximal rate determined for E897R_R898E, either with PS or 
PE, is intermediate between the individual rates of the point mutants, in fact equal to or close to the calculated 
average of these rates (Table 1, example for Vmax with PS: the average of 10 (for E897R) and 59 (for R898E) is 
34.5, compare with 35 (for E897R_R898E)), which means that R898E results in a gain-of-function when present 
together with E897R, contrary to its effect alone. Hence, E897 and R898 seem to interact, and this interaction 
is partly preserved when the residues swap positions. Collectively, the data obtained with the individual E897 
and R898 mutants and the swap mutant suggest that the lipid substrate comes close to the location of these res-
idues during the transport process, sensing the charges of both, and that these residues also interact with each 
other through a salt bridge. Another possible player in this region is the arginine R105 located in the exoplasmic 
loop between M1 and M2 (Fig. 5a). Indeed the slight reduction of the apparent affinity for the lipid substrate in 
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combination with reduced Vmax seen for mutation R105A shows that the lipid substrate senses R105, although 
less strongly than R898.
In the structural model (Fig. 5a) the side chain of R898 is sufficiently close to the aspartate D99 of M1 to allow 
formation of a salt bridge between them. However, the wild type-like Vmax in the presence of PS and wild type-like 
Figure 6. Alignment of the regions corresponding to the first six transmembrane segments of P4-ATPases 
and SERCA. Protein sequences of the bovine ATP8A2 studied here, the 14 human flippases, 4 yeast flippases, 
and one plant flippase (UniProt nos. from above: C7EXK4, Q9NTI2, Q9Y2Q0, O43520, P98198, O60423, 
Q8TF62, O75110, O43861, O60312, O94823, Q9P241, P98196, Q9Y2G3, Q8NB49, P32660, Q12675, Q12674, 
P39524, and Q9LI83) were aligned with rabbit SERCA1 Ca2+-ATPase (UniProt no. P04191) as previously 
described14. Letter colours denote positively (blue) or negatively (red) charged, polar (green), or hydrophobic 
(black) residues. The residues replaced in the three disease mutants studied here are indicated with arrowheads. 
Numbering refers to the bovine ATP8A2. Grey shading denotes the transmembrane helices identified in SERCA 
crystal structures. The human P4-ATPases are subdivided into classes of genetically most related proteins: Class 
1a (ATP8A1, ATP8A2), Class 1b (ATP8B1, ATP8B2, ATP8B3, ATP8B4), Class 2 (ATP9A, ATP9B), Class 5 
(ATP10A, ATP10B, ATP10D), and Class 6 (ATP11A, ATP11B, ATP11C)2.
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PS affinity of the D99A mutant (Table 1) indicate that such interaction is unimportant for PS binding. The model 
does not include the lipid substrate and, hence, does not show the structural adaptations to its binding. The actual 
rotamer of the R898 side chain may thus be different from that of the original model14, at least in the PS-bound 
state. As shown in Fig. 5b, an option is a rotamer forming a bond only with E897 and not with D99.
Consistent with the results of the functional analysis, the location of E897 and R898 in the exoplasmic M5-M6 
loop at the border of M6 would allow these residues to be among the first residues encountered by lipids destined 
for translocation, thus being part of an entry gate that contributes to selection of the lipid. The salt bridge between 
E897 and R898 could be important in preventing the negative charge of the E897 side chain from repelling the PS 
head group, thereby ensuring high affinity for PS. While glutamate or aspartate is present at the position corre-
sponding to bATP8A2 E897 in most P4-ATPases, the juxtaposed positively charged arginine is unique to ATP8A1 
and ATP8A2 (Fig. 6), which both have high specificity for PS. The PC flippase ATP8B1 has a pair of anionic 
carboxylic acid residues, E981 and D982, at the corresponding positions. According to the present results with 
R898D, the aspartate will markedly reduce the affinity for PS (Table 1). Therefore the aspartate may contribute 
to ensure PC selectivity of ATP8B1. On the other hand, not all PS flippases have a positively charged residue at 
the position corresponding to R898 in bATP8A2. A neutral residue is found in ATP11A and ATP11C (threonine 
and alanine, respectively), which both are well documented PS flippases8. The yeast PS flippase Drs2 likewise has 
a neutral residue (serine) at this position, and the yeast PC flippases Dnf1 and Dnf2 also have a neutral residue 
(tyrosine) here (Fig. 6). Thus, there is no clear correlation between the substrate specificity and the charge of the 
side chain at this position all through the P4-ATPase family members. Variation here might in fact be a physio-
logically important means of endowing the various PS flippases with differential PS affinity. To this can be further 
added the variation of the residue at the position corresponding bATP8A2 L308. The mammalian P4-ATPase 
classes each have their characteristic amino acid at this position: leucine for Class 1a (ATP8A1,A2), isoleucine for 
Class 1b (ATP8B1,B2,B3,B4), leucine for Class 2 (ATP9A,B), cysteine for Class 5 (ATP10A,B,D), and tyrosine for 
Class 6 (ATP11A,B,C) (Fig. 6, see class nomenclature in figure legend). Based on the present data for the mutants 
L308F and R898D (Table 1), the PS affinity of L308F is even lower than that of R898D. Due to the similar chemical 
properties of the tyrosine and phenylalanine side chains, the tyrosine present at this position in Class 6 flippases 
would be expected to further contribute to lower their PS affinity relative to Class 1a. A future challenge is there-
fore to experimentally determine the affinity of Class 6 flippases for the lipid substrate.
Methods
Flippase enzyme. The enzyme studied here is bovine ATP8A2 (bATP8A2, EC 3.6.3.1, UniProt C7EXK4). 
The applied procedures for mutagenesis, expression, purification, and reconstitution in lipid vesicles of wild type 
and mutant bATP8A2 with the accessory CDC50 subunit have previously been described in detail6, 14, 15. Briefly, 
selected mutations were introduced into bATP8A2 cDNA contained in a pcDNA3 plasmid vector by PCR. All 
constructs were verified by sequencing of the entire coding sequence. HEK293T cells were co-transfected with 
bATP8A2 and CDC50A cDNA. Cells were lysed and the flippase bATP8A2/CDC50A protein complex was 
immunoaffinity-purified using the Rho 1D4 antibody, which specifically recognizes a C-terminal nine amino acid 
1D4 tag on bATP8A224. Reconstitution of mutated or wild type bATP8A2/CDC50A in PC-containing vesicles by 
removal of detergent by dialysis made the protein suitable for storage.
ATPase activity measurements. To determine the lipid substrate dependence of ATPase activity, the pro-
teoliposomes were re-dissolved in assay buffer (9 mM CHAPS, 50 mM HEPES-NaOH (pH 7.5), 150 mM NaCl, 
11.75 mM MgCl2 and 1 mM DTT). PS (0–1000 µM) or PE (0–2000 µM) was added together with PC (maintaining 
a fixed total lipid concentration of 2.5 mg/mL). The lipids, PS (1,2-dioleoyl-sn-glycero-3-phospho-serine, 18:1 PS, 
cat. no. 840035), PE (1,2-dioleoyl-sn-glycero-3-phospho-ethanolamine, 18:1 (Δ9-Cis) PE, cat. no. 850725), and 
PC (L-α-phosphatidylcholine, egg lecithin from chicken, >99% pure, cat. no. 840051), were from Avanti Polar 
Lipids (Alabaster, AL). The ATPase reaction (running for 15 min at 37 °C, linear time dependence in this range) 
was started by addition of ATP (7.5 mM) and terminated with SDS (12%). The amount of liberated phosphate was 
quantified by colorimetric analysis6.
Data analysis and statistics. The K0.5 values for activation by the lipid substrates were extracted by curve 
fitting using the SigmaPlot program (SPSS, Inc.) for nonlinear regression (see legend to Fig. 3 for equation used). 
P-values for comparison of wild type and mutant regressions, expression and Vmax values were calculated with 
SigmaPlot using the one-way ANOVA for multiple comparisons versus control group with Holm-Sidak test. Error 
bars in figures and ± in tables indicate standard error (s.e.m.). Structural figures were prepared using PyMOL 
software.
Data availability statement. All source data for figures and tables in the present article are available from 
the corresponding author on reasonable request.
References
 1. Folmer, D. E., Oude Elferink, R. P. J. & Paulusma, C. C. P4 ATPases - Lipid flippases and their role in disease. Biochim. Biophys. Acta 
1791, 628–635 (2009).
 2. Andersen, J. P. et al. P4-ATPases as phospholipid flippases - structure, function, and enigmas. Front. Physiol. 7, 275, doi:10.3389/
fphys (2016).
 3. Segawa, K. et al. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science 344, 
1164–1168 (2014).
 4. Bevers, E. M. & Williamson, P. L. Getting to the outer leaflet: physiology of phosphatidylserine exposure at the plasma membrane. 
Physiol. Rev. 96, 605–645 (2016).
www.nature.com/scientificreports/
1 1Scientific RePoRTS | 7: 10418  | DOI:10.1038/s41598-017-10741-z
 5. Sebastian, T. T., Baldridge, R. D., Xu, P. & Graham, T. R. Phospholipid flippases: Building asymmetric membranes and transport 
vesicles. Biochim. Biophys. Acta 1821, 1068–1077 (2012).
 6. Coleman, J. A., Kwok, M. C. M. & Molday, R. S. Localization, purification, and functional reconstitution of the P4-ATPase Atp8a2, 
a phosphatidylserine flippase in photoreceptor disc membranes. J. Biol. Chem. 284, 32670–32679 (2009).
 7. Ding, J. et al. Identification and functional expression of four isoforms of ATPase II, the putative aminophospholipid translocase. 
Effect of isoform variation on the ATPase activity and phospholipid specificity. J. Biol. Chem. 275, 23378–23386 (2000).
 8. Takatsu, H. et al. Phospholipid flippase activities and substrate specificities of human type IV P-type ATPases localized to the plasma 
membrane. J. Biol. Chem. 289, 33543–33556 (2014).
 9. Naito, T. et al. Phospholipid flippase ATP10A translocates phosphatidylcholine and is involved in plasma membrane dynamics. J. 
Biol. Chem. 290, 15004–15017 (2015).
 10. Onat, O. E. et al. Missense mutation in the ATPase, aminophospholipid transporter protein ATP8A2 is associated with cerebellar 
atrophy and quadrupedal locomotion. Eur. J. Hum. Genet. 21, 281–285 (2012).
 11. Martín-Hernández, E. et al. New ATP8A2 gene mutations associated with a novel syndrome: encephalopathy, intellectual disability, 
severe hypotonia, chorea and optic atrophy. Neurogenetics 17, 259–263 (2016).
 12. Bull, L. N. et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18, 219–224 (1998).
 13. Klomp, L. W. J. et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 40, 27–38 (2004).
 14. Vestergaard, A. L. et al. Critical roles of isoleucine-364 and adjacent residues in a hydrophobic gate control of phospholipid transport 
by the mammalian P4-ATPase ATP8A2. Proc. Natl. Acad. Sci. USA 111, E1334–1343 (2014).
 15. Coleman, J. A., Vestergaard, A. L., Molday, R. S., Vilsen, B. & Andersen, J. P. Critical role of a transmembrane lysine in 
aminophospholipid transport by mammalian photoreceptor P4-ATPase ATP8A2. Proc. Natl. Acad. Sci. USA 109, 1449–1454 (2012).
 16. Baldridge, R. D. & Graham, T. R. Identification of residues defining phospholipid flippase substrate specificity of type IV P-type 
ATPases. Proc. Natl. Acad. Sci. USA 109, E290–298 (2012).
 17. Stone, A. & Williamson, P. Outside of the box: recent news about phospholipid translocation by P4 ATPases. J. Chem. Biol. 5, 
131–136 (2012).
 18. Baldridge, R. D. & Graham, T. R. Two-gate mechanism for phospholipid selection and transport by type IV P-type ATPases. Proc. 
Natl. Acad. Sci. USA 110, E358–E367 (2013).
 19. Numakura, C., Abukawa, D., Kimura, T., Tanabe, S. & Hayasaka, K. A case of progressive familial intrahepatic cholestasis type 1 with 
compound heterozygous mutations of ATP8B1. Pediatr. Int. 53, 107–110 (2011).
 20. Azouaoui, H. et al. High phosphatidylinositol 4-phosphate (PI4P)-dependent ATPase activity for the Drs2p-Cdc50p flippase after 
removal of its N- and C-terminal extensions. J. Biol. Chem. 292, 7954–7970 (2017).
 21. Stone, A. et al. Biochemical characterization of P4-ATPase mutations identified in patients with progressive familial intrahepatic 
cholestasis. J. Biol. Chem. 287, 41139–41151 (2012).
 22. Roland, B. P. & Graham, T. R. Directed evolution of a sphingomyelin flippase reveals mechanism of substrate backbone 
discrimination by a P4-ATPase. Proc. Natl. Acad. Sci. U S A 113, E4460–E4466 (2016).
 23. Coleman, J. A. & Molday, R. S. Critical role of the beta-subunit CDC50A in the stable expression, assembly, subcellular localization, 
and lipid transport activity of the P4-ATPase ATP8A2. J. Biol. Chem. 286, 17205–17216.
 24. Wong, J. P., Reboul, E., Molday, R. S. & Kast, J. A carboxy-terminal affinity tag for the purification and mass spectrometric 
characterization of integral membrane proteins. J. Proteome Res. 8, 2388–2396 (2009).
Acknowledgements
This study was funded in part by grants to J.P.A. from the Danish Medical Research Council, the Novo Nordisk 
Foundation, and the Lundbeck Foundation, and to R.S.M. from the Canadian Institutes for Health Research 
(PJT148649) and the National Institutes of Health (EY02422). R.H.G. was supported by a studentship from the 
MEMBRANES Centre, Aarhus University.
Author Contributions
R.H.G., A.L.V., and J.P.A. designed the research. R.H.G., L.S.M., S.A.M., A.L.V., and J.P.A. performed the research. 
R.H.G., L.S.M., S.A.M., B.V., R.S.M., A.L.V., and J.P.A. analysed data. R.H.G., L.S.M., S.A.M., B.V., R.S.M., A.L.V., 
and J.P.A. wrote the paper.
Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
